Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer


Nanjing Medical University

Status and phase

Phase 2


Colorectal Neoplasms


Drug: Bevacizumab
Drug: Pemetrexed
Drug: S-1

Study type


Funder types




Details and patient eligibility


Limited agents are optional after standard first and second line treatment for mCRC. Only Regorafenib and Fruquintinib are approved in China. PFS of these targeted drugs are not very long. Pemetrexed has shown significant efficacy in advanced lung cancer regarding PFS and OS with controllable toxicity. S-1 has been used in colorectal cancer with promising outcomes. Bevacizumab is also an important monoclonal antibody which could make benefits in treated patients. This study is aimed to explore the efficacy, safety in advanced colorectal cancer failed to standard therapy in Chinese population.




18 to 75 years old


No Healthy Volunteers

Inclusion criteria

  • Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.
  • Subjects with metastatic colorectal cancer(CRC) (Stage IV).
  • Subjects must have failed at least two lines of prior treatment, which must include a fluoropyrimidine, oxaliplatin and irinotecan.
  • Subjects have failed or refused third-line treatment with regorafenib or fruquintinib.
  • Subjects treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy.
  • Subjects who have withdrawn from standard treatment due to unacceptable toxicity and precluding retreatment with the same agent prior to progression of disease will also be allowed.
  • Prior treatment with bevacizumab and/or cetuximab will be allowed, but the use of bevacizumab should be no more than one single line treatment.
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version necessary.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
  • Life expectancy of at least 3 months.
  • Adequate bone marrow, liver, cardiac and renal function as assessed by the laboratory required by protocol.
  • Assigned informed consent.

Exclusion criteria

  • Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
  • Participants of other clinical trial within 4 weeks.
  • Diseases which will impact the absorption of S-1, eg. dysphagia, chronic diarrhea, bowl obstruction
  • Hemorrhage events of ≥grade 3 within 4 weeks.
  • Known central nervous system metastasis.
  • Uncontrolled hypertension. (Systolic blood pressure 140 mmHg or diastolic pressure 90 mmHg despite optimal medical management). Unstable angina,congestive heart failure,Myocardial infarction, Cardiac arrhythmias requiring anti-arrhythmic therapy.
  • Urine protein ≥++ and 24h urine protein more than 1.0g.
  • Chronically green wound or bone fracture.
  • Arterial or venous thrombotic or embolic events.
  • Tumor invading important blood vessel with high risk of severe hemorrhage.
  • Current active bleeding or any surgery taken within 2 months.
  • Abnormal coagulation function.
  • Thromboemboli events within 6 months.
  • Immune diseases or organ transplantation history.

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

0 participants in 1 patient group

Pemetrexed + S-1 + Bevacizumab
Experimental group
Pemetrexed 500 mg/m2 d1+ S-1 (20mg、25mg), capsule, 40~60mg, Bid,p.o, d1~14 + Bevacizumab 7.5 mg/kg d1; Repeated every 3 weeks
Drug: S-1
Drug: Pemetrexed
Drug: Bevacizumab

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems